作为抗糖尿病和抗糖化剂的有前途的化黄酸的合成
Rita Hairani1,2, Warinthorn Chavasiri3
1Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
Scientific reports
|July 15, 2025
概括
化黄类药物表现出强大的抗糖尿病和抗糖化作用. 这些化合物,特别是8-bromobaicalein和6,8-dibromoluteolin,有效地抑制关键酶和糖化,这表明可以增强治疗潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 糖尿病是一种全球性健康问题,其特点是高血糖.
- 酶抑制 (α-葡萄糖酶,α-氨基酶) 和抗糖化是糖尿病管理的关键策略.
- 黄酸是具有潜在治疗益处的天然化合物.
研究的目的:
- 合成和评估化黄素的抗糖尿病和抗糖化作用.
- 为了识别具有增强抑制作用的强效黄类衍生物.
- 了解有关替代的结构-活性关系.
主要方法:
- 使用化剂半合成十二种天然的黄素及其化衍生物.
- 在体外评估对α-葡萄糖酶和α-氨基酶的抑制活性.
- 通过用甲基酸 (methylglyoxal) 进行牛血清白蛋白 (BSA) 糖化试验,评估抗糖化活性.
主要成果:
- 合成了两种新的化合物,即6,8 - - 二胺 (F3a) 和6,8 - - 二胺阿尔皮尼丁 (F10a).
- 8-Bromobaicalein (F4a) 和6,8-dibromoluteolin (F3a) 分别表现出强大的混合类型抑制α-葡萄糖酶和α-氨基酶.
- 6,8-Dibromochrysin (F1a) 显示显著抑制了BSA-糖化.
结论:
- 黄酸盐的化可以增强它们的抗糖尿病和抗糖化特性.
- 原子的电子和疏水作用有助于观察到的生物活性.
- 化黄类化合物代表了开发新型抗糖尿病药物的有希望的候选人.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
267
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
267
Oral Hypoglycemic Agents: Glinides
268
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
268
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene
6.4K
Bromination and chlorination of aromatic rings by electrophilic aromatic substitution reactions are easily achieved, but fluorination and iodination are difficult to achieve. Fluorine is so reactive that its reaction with benzene is difficult to control, resulting in poor yields of monofluoroaromatic products. To address this, Selectfluor reagent is used as a fluorine source in which a fluorine atom is bonded to a positively charged nitrogen.
6.4K
Oral Hypoglycemic Agents: Sulfonylureas
345
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
345
Insulin: Biosynthesis, Chemistry, and Preparation
566
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
306
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
306


